These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9642622)

  • 21. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).
    Balabanov R; Lisak D; Beaumont T; Lisak RP; Dore-Duffy P
    Clin Diagn Lab Immunol; 2001 Nov; 8(6):1196-203. PubMed ID: 11687463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
    Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
    Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis of clinical trials with copolymer 1 in multiple sclerosis.
    La Mantia L; Milanese C; D'Amico R
    Eur Neurol; 2000; 43(4):189-93. PubMed ID: 10828647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy with glatiramer acetate for multiple sclerosis.
    Munari L; Lovati R; Boiko A
    Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended use of glatiramer acetate (Copaxone) for MS.
    Greenstein JI
    Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765
    [No Abstract]   [Full Text] [Related]  

  • 26. Glatiramer acetate for multiple sclerosis.
    La Mantia L; Munari LM; Lovati R
    Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
    Filippi M; Wolinsky JS; Comi G;
    Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS;
    Neurology; 2001 Dec; 57(12 Suppl 5):S16-24. PubMed ID: 11902590
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
    Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
    Dhib-Jalbut S
    Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    J Neurol; 2000 Sep; 247(9):713. PubMed ID: 11081814
    [No Abstract]   [Full Text] [Related]  

  • 33. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
    Sormani MP; Bruzzi P; Comi G; Filippi M
    Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.
    Drago F; Brusati C; Mancardi G; Murialdo A; Rebora A
    Arch Dermatol; 1999 Oct; 135(10):1277-8. PubMed ID: 10522686
    [No Abstract]   [Full Text] [Related]  

  • 35. The treatment of multiple sclerosis: current and future.
    Polman CH; Hartung HP
    Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
    Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
    Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
    Ramtahal J; Jacob A; Das K; Boggild M
    J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy in multiple sclerosis, Part 2.
    Becker CC; Gidal BE; Fleming JO
    Am J Health Syst Pharm; 1995 Oct; 52(19):2105-20; quiz 2132-4. PubMed ID: 8535945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Disease modifying therapies in multiple sclerosis].
    Fukaura H
    Nihon Rinsho; 2014 Nov; 72(11):2015-22. PubMed ID: 25518387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.